News
FDA asks Novavax for post-marketing data pledge amid stalled COVID shot review
On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—warned that the mass downsizing at the agency could hamstring the regulator’s ability to review drugs beginning in 2026 or 2027.
Funded by an unrestricted gift of $240,000 from Alumbra, a foundation established by philanthropist Christy Walton, the ...
A team of health experts is launching an independent project that could start its own vaccine evaluation and guidelines — ...
Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.
Researchers have developed a tau-targeting vaccine that could help prevent the progression of Alzheimer’s disease by ...
Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...
The Slovak government halted purchases of COVID-19 vaccines on Wednesday pending a review of their safety by the Slovak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback